Cargando…

Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer

Tumor lysis syndrome (TLS) is an oncological life-threatening complication characterized by hyperuricemia, hyperphosphatemia, and hyperkalemia, which can lead to acute renal failure, cardiac arrhythmias, cardiac arrest and seizures. Although TLS is a rare complication in patients with non-hematologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Tomomichi, Ohta, Tsuyoshi, Narumi, Megumi, Sakaki, Hirotsugu, Seino, Manabu, Sudo, Takeshi, Nagase, Satoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966519/ https://www.ncbi.nlm.nih.gov/pubmed/29845102 http://dx.doi.org/10.1016/j.gore.2018.02.005

Ejemplares similares

Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab
por: Fukase, Mika, et al.
Publicado: (2020)

Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature
por: Nakamura, Fumihiro, et al.
Publicado: (2019)

Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer
por: Sendo, Kanako, et al.
Publicado: (2022)

Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
por: Seino, Manabu, et al.
Publicado: (2018)

Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
por: Seino, Manabu, et al.
Publicado: (2021)

Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma
por: Idei, Urara, et al.
Publicado: (2023)

xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma
por: Sugiyama, Akiko, et al.
Publicado: (2020)

Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer
por: Tokunaga, Megumi, et al.
Publicado: (2022)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma
por: Song, Caiping, et al.
Publicado: (2018)

Spontaneous Tumor Lysis Syndrome Due to Endometrial Carcinoma
por: Chango Azanza, Juan Jose, et al.
Publicado: (2020)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Impact of adjuvant chemotherapy on the overall survival of patients with resectable bulky small cell neuroendocrine cervical cancer: a JSGO-JSOG joint study
por: Seino, Manabu, et al.
Publicado: (2022)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
por: Armstrong, Stephen R, et al.
Publicado: (2012)

Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma
por: Fujiwara, Kazuko, et al.
Publicado: (2011)

The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
por: Okada, Masashi, et al.
Publicado: (2016)

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
por: Ueda, Yutaka, et al.
Publicado: (2010)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Spontaneous Tumor Lysis Syndrome in a Patient with a Dedifferentiated Endometrial Adenocarcinoma
por: Harada, Shinichi, et al.
Publicado: (2017)

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
por: Murakami, Isao, et al.
Publicado: (2023)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Tumour lysis syndrome in a patient with undifferentiated endometrial stromal sarcoma
por: Ahmed, Zeeshan, et al.
Publicado: (2019)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Honeycomb-like Structured Film, a Novel Therapeutic Device, Suppresses Tumor Growth in an In Vivo Ovarian Cancer Model
por: Ohta, Tsuyoshi, et al.
Publicado: (2022)

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
por: AOKI, TAKUYA, et al.
Publicado: (2014)

A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
por: Isonishi, Seiji, et al.
Publicado: (2013)

A case of primary metastatic glassy cell carcinoma of the uterine cervix that responded to combined docetaxel and carboplatin()
por: Ukita, Yuji, et al.
Publicado: (2013)

Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.
por: Rantanen, V., et al.
Publicado: (1994)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Onaga, Ryutaro, et al.
Publicado: (2023)

Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin
por: Yazawa, Hiroyuki, et al.
Publicado: (2017)

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
por: de Moraes, Francisco Cezar Aquino, et al.
Publicado: (2023)

Tumor lysis syndrome in advanced and high-grade endometrial cancers: A case report and review of the literature
por: Zhao, Johnathan, et al.
Publicado: (2021)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Tumor-Infiltrating CD8-Positive T-Cells Associated with MMR and p53 Protein Expression Can Stratify Endometrial Carcinoma for Prognosis
por: Munakata, Satoru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j71r4po4ktgp3k12ob376vi78r